表紙
市場調査レポート

消化管関連の各種提携契約:契約条件・合意内容

Global Gastrointestinal Partnering 2010-2016: Deal trends, players and financials

発行 Current Partnering, a division of Wildwood Ventures Limited 商品コード 250304
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
消化管関連の各種提携契約:契約条件・合意内容 Global Gastrointestinal Partnering 2010-2016: Deal trends, players and financials
出版日: 2016年09月01日 ページ情報: 英文
概要

当レポートでは、消化管関連の各種提携契約について調査分析し、近年における各種契約の動向、大規模契約および大手医薬品事業者による契約の概要、契約区分・開発ステージ・技術区分・適応症区分別のディレクトリなどをまとめ、概略下記の構成でお届けいたします。

エグゼクティブサマリー

第1章 イントロダクション

第2章 消化管関連の各種契約の動向

  • イントロダクション
  • 過去数年における消化管関連の提携
  • 大手製薬会社による契約活動
  • 消化管関連の事業に積極的でない大手製薬会社
  • 消化管関連の提携:契約タイプ別
  • 消化管関連の提携:産業部門別
  • 消化管関連の提携:開発ステージ別
  • 消化管関連の提携:技術タイプ別
  • 消化管関連の提携:適応症別
  • 平均契約期間

第3章 主要契約

  • イントロダクション
  • 主要契約:取引額別
  • 大手製薬会社のかかわる主要契約

第4章 大手製薬会社による契約

  • イントロダクション
  • 大手製薬会社による提携契約の利用法
  • 企業プロファイル

第5章 契約ディレクトリ

  • イントロダクション
  • 契約タイプ別
    • 資産購入
    • 大手によるアウトライセンシング
    • 共同開発
    • 共同R&D
    • 共同販売
    • サービス契約
    • 共同プロモーション
    • 開発
    • 流通
    • 株式購入
    • ライセンシング
    • 訴訟
    • ローン
    • 製造
    • マーケティング
    • オプション
    • プロモーション
    • 研究
    • 和解関連
    • サブライセンス
    • 供給
    • 技術移転
    • 終了
  • 開発ステージ別
    • 創薬
    • 製剤設計
    • 上市
    • フェーズI
    • フェーズII
    • フェーズIII
    • 前臨床
    • 規制
  • 技術タイプ別
    • 抗体
    • 生物学的化合物
    • 細胞治療
    • デバイス
    • 診断
    • 創薬ツール
    • ドラッグデリバリー
    • イネーブリング技術
    • 設備
    • 装置
    • ゲノミクス
    • イメージング
    • 天然製品
    • オリゴヌクレオチド
    • ペプチド
    • プロテオミクス
    • 研究サービス
    • 研究サプライ
    • スクリーニング
    • 小分子
    • ソフトウェアツール
    • 幹細胞

第6章 消化管関連の契約:適応症別

  • イントロダクション
  • 適応症別
    • 消化管
    • 虫垂炎
    • セリアック病
    • 食道逆流
    • 食道炎
    • 胃炎
    • 胃腸炎
    • 痔(痔核)
    • ヘルニア
    • 炎症性腸疾患
    • クローン病
    • 潰瘍性大腸炎
    • 過敏性腸症候群
    • 吸収不良
    • 栄養不良
    • 膵炎
    • 消化性潰瘍
    • 胃潰瘍
    • 腹痛
    • 腹水
    • 排便
    • 便秘
    • 下痢
    • 消化不良
    • 嚥下障害
    • 黄疸
    • 嘔吐

第7章 提携機会

  • オンラインパートナリング
  • パートナリングイベント
  • 関連資料

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: CP2214

The Global Gastrointestinal Partnering 2010-2016: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the gastrointestinal partnering deals and agreements entered into by the worlds leading healthcare companies

Description

Global Gastrointestinal Partnering 2010 to 2016 provides the full collection of Gastrointestinal disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Trends in Gastrointestinal partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Gastrointestinal partnering agreement structure

Gastrointestinal partnering contract documents

Top Gastrointestinal deals by value

Most active Gastrointestinal dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Gastrointestinal disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Gastrointestinal deals.

The report presents financial deal terms values for Gastrointestinal deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Gastrointestinal dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Gastrointestinal dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Gastrointestinal deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Gastrointestinal dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Gastrointestinal deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Gastrointestinal partnering deals by specific Gastrointestinal target announced since 2010. The chapter is organized by specific Gastrointestinal therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Gastrointestinal partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Gastrointestinal partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Gastrointestinal technologies and products.

Report scope

Global Gastrointestinal Partnering 2010 to 2016 is intended to provide the reader with an in-depth understanding and access to Gastrointestinal trends and structure of deals entered into by leading companies worldwide.

Global Gastrointestinal Partnering 2010 to 2016 includes:

  • Trends in Gastrointestinal dealmaking in the biopharma industry since 2010
  • Analysis of Gastrointestinal deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Gastrointestinal deal contract documents
  • Comprehensive access to over 3500 Gastrointestinal deal records
  • The leading Gastrointestinal deals by value since 2010
  • Most active Gastrointestinal dealmakers since 2010
  • The report includes deals for the following indications: Appendicitis, Celiac disease, Esophageal reflux, Esophagitis, Gastritis, Gastroenteritis, Hemorrhoids (haemorrhoids), Hernia, Inflammatory bowel disease, Crohn's disease, Ulcerative colitis, Irritable bowel syndrome, Malabsorption, Malnutrition, Pancreatitis, Peptic ulce, Gastric ulcer, Duodenal ulcer, Abdominal pain, Ascites, Bowel movement, Constipation, Diarrhea, Jaundice, Vomitting, plus other gastrointestinal indications.

In Global Gastrointestinal Partnering 2010 to 2016, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication
  • Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Gastrointestinal Partnering 2010-2016 report provides comprehensive access to available deals and contract documents for over 400 gastrointestinal deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Gastrointestinal Partnering 2010 to 2016 provides the reader with the following key benefits:

  • In-depth understanding of Gastrointestinal deal trends since 2010
  • Access Gastrointestinal deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between Gastrointestinal partner companies
  • Comprehensive access to over 750 links to actual Gastrointestinal deals entered into by the world's biopharma companies
  • Indepth review of Gastrointestinal deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner Gastrointestinal opportunities
  • Uncover companies actively partnering Gastrointestinal opportunities

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Gastrointestinal dealmaking

  • 2.1. Introduction
  • 2.2. Gastrointestinal partnering over the years
  • 2.3. Gastrointestinal partnering by deal type
  • 2.4. Gastrointestinal partnering by industry sector
  • 2.5. Gastrointestinal partnering by stage of development
  • 2.6. Gastrointestinal partnering by technology type
  • 2.7. Gastrointestinal partnering by therapeutic indication

Chapter 3 -Financial deal terms for Gastrointestinal partnering

  • 3.1. Introduction
  • 3.2. Disclosed financials terms for Gastrointestinal partnering
  • 3.3. Gastrointestinal partnering headline values
  • 3.4. Gastrointestinal deal upfront payments
  • 3.5. Gastrointestinal deal milestone payments
  • 3.6. Gastrointestinal royalty rates

Chapter 4 - Leading Gastrointestinal deals and dealmakers

  • 4.1. Introduction
  • 4.2. Most active in Gastrointestinal partnering
  • 4.3. List of most active dealmakers in Gastrointestinal
  • 4.4. Top Gastrointestinal deals by value

Chapter 5 - Gastrointestinal contract document directory

  • 5.1. Introduction
  • 5.2. Gastrointestinal partnering deals where contract document available

Chapter 6 - Gastrointestinal dealmaking by therapeutic target

  • 6.1. Introduction
  • 6.2. Deals by Gastrointestinal therapeutic target

Appendices

  • Appendix 1 - Directory of Gastrointestinal deals by company A-Z 2010 to 2016
  • Appendix 2 - Directory of Gastrointestinal deals by deal type 2010 to 2016
  • Appendix 3 - Directory of Gastrointestinal deals by stage of development 2010 to 2016
  • Appendix 4 - Directory of Gastrointestinal deals by technology type 2010 to 2016
  • Further reading on dealmaking
  • Deal type definitions
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent report titles from CurrentPartnering
  • Table of figures
  • Figure 1: Gastrointestinal partnering since 2010
  • Figure 2: Gastrointestinal partnering by deal type since 2010
  • Figure 3: Gastrointestinal partnering by industry sector since 2010
  • Figure 4: Gastrointestinal partnering by stage of development since 2010
  • Figure 5: Gastrointestinal partnering by technology type since 2010
  • Figure 6: Gastrointestinal partnering by indication since 2010
  • Figure 7: Gastrointestinal deals with a headline value
  • Figure 8: Gastrointestinal deals with upfront payment values
  • Figure 9: Gastrointestinal deals with milestone payment
  • Figure 10: Gastrointestinal deals with royalty rates
  • Figure 11: Active Gastrointestinal dealmaking activity- 2010 to 2016
  • Figure 12: Top Gastrointestinal deals by value since 2010
Back to Top